Results 51 to 60 of about 68,651 (161)
Frontiers in OncologyBackgroundThe ubiquitin proteasome system is involved in the regulation of cellular gene transcription and cellular receptor function through the degradation of proteins, thus affecting tumorigenesis and development.
Yan-Hui Yang +10 more
doaj +1 more source
Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma
World Journal of Surgical Oncology, 2021 Background Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be a prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection. Methods One
Shinichiro Yamada +8 more
doaj +1 more source
Preclinical models of pancreatic ductal adenocarcinoma [PDF]
The Journal of Pathology, 2015 AbstractPancreatic ductal adenocarcinoma (PDA) is one of the most difficult human malignancies to treat. The 5‐year survival rate of PDA patients is 7% and PDA is predicted to become the second leading cancer‐related cause of death in the USA. Despite intensive efforts, the translation of findings in preclinical studies has been ineffective, due ...
Hwang, Chang-Il +3 more
openaire +5 more sources
Molecular Cancer, 2018 Background Defective autophagy is thought to contribute to the pathogenesis of many diseases, including cancer. Human plasmacytoma variant translocation 1 (PVT1) is an oncogenic long non-coding RNA that has been identified as a prognostic biomarker in ...
Fengting Huang +9 more
doaj +1 more source
Tumor Biology, 2017 Pancreatic ductal adenocarcinoma is a highly malignant tumor with poor prognosis, and the biomarkers for the early diagnosis, targeting therapy, and prognosis are still not clinically available.
Xin Luo +7 more
doaj +1 more source
Emerging concepts in the management of pancreatic ductal adenocarcinoma
Laparoscopic, Endoscopic and Robotic Surgery, 2019 Pancreatic ductal adenocarcinoma is characterised by poor oncological outcomes with curative treatment only possible for a minority. Symptoms are dependent on the stage of the disease and location within the pancreas with constitutional decline often ...
Sanket Srinivasa, Rowan Parks
doaj +1 more source
Bangladesh Journal of PharmacologyGemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu +5 more
doaj +1 more source
BMC Surgery, 2019 Background The perioperative factors predicting or influencing early pancreatic ductal adenocarcinoma recurrence are unclear. This study attempted to identify the predictive factors for early pancreatic ductal adenocarcinoma recurrence post ...
Hironobu Suto +9 more
doaj +1 more source
Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma
Signal Transduction and Targeted TherapyPancreatic ductal adenocarcinoma is traditionally characterized as a glycolytic tumor. However, the extent and clinical relevance of its metabolic heterogeneity remain poorly understood.
Ugo Chianese +18 more
doaj +1 more source
Zhongguo aizheng zazhi, 2019 Background and purpose: Monocarboxylate transporter 1 (MCT1) is commonly seen to be significantly overexpressed in cancer tissues that takes charge of transporting the lactate, pyruvate and their derivatives belonging to monocarboxylate in cells. However,
张 敏, 王琳娜, 孙 超
doaj